GH Research (NASDAQ:GHRS) Shares Up 2.6%

GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price traded up 2.6% on Monday . The stock traded as high as $11.60 and last traded at $11.48. 45,201 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 137,380 shares. The stock had previously closed at $11.19.

Wall Street Analyst Weigh In

Several research firms have commented on GHRS. JMP Securities dropped their target price on GH Research from $50.00 to $39.00 and set a "market outperform" rating for the company in a research report on Friday, March 1st. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, March 4th.

GH Research Price Performance

The company has a market capitalization of $609.79 million, a P/E ratio of -17.24 and a beta of 0.84. The stock has a 50-day moving average price of $9.47 and a 200-day moving average price of $7.78.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). Sell-side analysts anticipate that GH Research PLC will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in GH Research by 13,760.0% in the fourth quarter. Bank of America Corp DE now owns 2,772 shares of the company's stock worth $27,000 after purchasing an additional 2,752 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in GH Research by 246.2% in the first quarter. Tower Research Capital LLC TRC now owns 4,075 shares of the company's stock worth $33,000 after purchasing an additional 2,898 shares in the last quarter. Northern Trust Corp bought a new stake in GH Research in the fourth quarter worth approximately $59,000. Renaissance Technologies LLC bought a new stake in GH Research in the first quarter worth approximately $86,000. Finally, State Street Corp bought a new stake in GH Research in the third quarter worth approximately $127,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.